Your browser is no longer supported. Please, upgrade your browser.
Settings
ACAD ACADIA Pharmaceuticals Inc. daily Stock Chart
ACAD [NASD]
ACADIA Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.52 Insider Own0.10% Shs Outstand124.73M Perf Week4.52%
Market Cap2.19B Forward P/E- EPS next Y-0.66 Insider Trans-17.55% Shs Float124.65M Perf Month11.05%
Income-187.00M PEG- EPS next Q-0.45 Inst Own100.00% Short Float14.19% Perf Quarter-12.01%
Sales158.50M P/S13.83 EPS this Y23.20% Inst Trans1.80% Short Ratio5.32 Perf Half Y-37.77%
Book/sh2.44 P/B7.20 EPS next Y66.70% ROA-63.70% Target Price50.14 Perf Year-39.30%
Cash/sh2.39 P/C7.36 EPS next 5Y38.30% ROE-71.50% 52W Range14.51 - 41.20 Perf YTD-41.61%
Dividend- P/FCF- EPS past 5Y-36.60% ROI-67.00% 52W High-58.54% Beta3.68
Dividend %- Quick Ratio7.30 Sales past 5Y91.10% Gross Margin94.30% 52W Low17.71% ATR1.09
Employees425 Current Ratio7.40 Sales Q/Q219.60% Oper. Margin- RSI (14)50.77 Volatility6.00% 6.85%
OptionableYes Debt/Eq0.00 EPS Q/Q39.70% Profit Margin- Rel Volume0.69 Prev Close17.58
ShortableYes LT Debt/Eq0.00 EarningsAug 03 BMO Payout- Avg Volume3.32M Price17.08
Recom2.00 SMA202.44% SMA50-0.83% SMA200-32.36% Volume2,286,178 Change-2.84%
Oct-06-17Resumed Goldman Neutral
Nov-11-16Initiated Goldman Neutral
Nov-08-16Upgrade BofA/Merrill Neutral → Buy
Oct-19-16Resumed ROTH Capital Neutral
Oct-04-16Initiated Leerink Partners Mkt Perform $34
Jun-22-16Downgrade BofA/Merrill Buy → Neutral
May-03-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-30-16Reiterated Piper Jaffray Overweight $39 → $44
Feb-08-16Initiated BofA/Merrill Buy $40
Jan-22-16Upgrade Piper Jaffray Neutral → Overweight
Aug-27-15Upgrade Piper Jaffray Neutral → Overweight $48
Aug-07-15Reiterated Needham Buy $38 → $49
Aug-07-15Downgrade Piper Jaffray Overweight → Neutral
Apr-16-15Initiated Leerink Partners Outperform $48
Mar-12-15Reiterated Needham Buy $40 → $38
Feb-24-15Initiated H.C. Wainwright Buy $50
Feb-06-15Resumed ROTH Capital Buy $42
Dec-22-14Reiterated Needham Buy $26 → $40
Aug-07-13Reiterated Needham Buy $16 → $26
Aug-07-13Reiterated Ladenburg Thalmann Buy $15 → $24
Jul-19-18 04:05PM  ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary Business Wire
10:15AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ACADIA Pharmaceuticals Inc. (ACAD) PR Newswire
07:45AM  Breakfast Technical Briefing on Avid Bioservices and Three Other Additional Biotech Stocks ACCESSWIRE
Jul-18-18 11:55AM  ACADIA Pharmaceuticals, Inc. (ACAD) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws PR Newswire
08:10AM  Today's Research Reports on Stocks to Watch: AVEO Pharmaceuticals and ACADIA Pharmaceuticals ACCESSWIRE
Jul-17-18 05:34PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire +7.65%
03:36PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against ACADIA Pharmaceuticals Inc. ACAD Business Wire
10:30AM  Glancy Prongay & Murray LLP Continues Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD) Business Wire
Jul-16-18 07:30AM  INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors Business Wire
Jul-13-18 04:08PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD) Business Wire
09:47AM  5 Big Pharma Stocks Investors Love Right Now InvestorPlace
08:17AM  Better Buy: Acadia Pharmaceuticals vs. Eli Lilly Motley Fool
Jul-11-18 04:35PM  Hagens Berman Alerts Investors in ACADIA Pharmaceuticals Inc. (ACAD) to the Firm's Investigation of Possible Disclosure Violations PR Newswire
Jul-09-18 09:09PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors Business Wire -6.78%
07:12PM  Why ACADIA Pharmaceuticals Stock Is Falling Today InvestorPlace
06:06PM  Bragar Eagel & Squire, P.C. is Investigating ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
01:08PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of ACADIA Pharmaceuticals Inc. GlobeNewswire
08:20AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Ionis Pharmaceuticals ACCESSWIRE
Jul-08-18 06:31AM  The 3 Worst Biotech Stocks of 2018 (So Far) Motley Fool
Jun-29-18 10:37AM  Why Acadia Pharmaceuticals Is Soaring Today Motley Fool
07:30AM  ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin) Business Wire
Jun-21-18 08:20AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Immunomedics ACCESSWIRE -6.45%
Jun-14-18 08:10AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Clovis Oncology ACCESSWIRE -5.13%
Jun-13-18 09:00AM  ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 20, 2018 Business Wire -8.43%
Jun-06-18 09:00AM  ACADIA Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on June 13, 2018 Business Wire
Jun-01-18 07:20AM  Stock Performance Review on ACADIA Pharma and Three Other Biotech Stocks ACCESSWIRE
May-23-18 06:02AM  Is Acadia Pharmaceuticals (ACAD) a Buy? Motley Fool
May-18-18 02:31PM  Better Buy: Acadia Pharmaceuticals vs. Biogen Motley Fool
May-15-18 06:11PM  Edited Transcript of ACAD earnings conference call or presentation 4-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-08-18 09:00AM  ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018 Business Wire
May-07-18 09:31AM  Are These 2 Biotech Laggards Ready to Rebound? Motley Fool
08:10AM  Todays Research Reports on Stocks to Watch: ACADIA Pharmaceuticals and Portola Pharmaceuticals ACCESSWIRE
07:20AM  Blog Exposure - Alnylam Pharma Attained Alignment with FDA on Pivotal Study Design for Lumasiran for Treatment of Primary Hyperoxaluria Type 1 ACCESSWIRE
May-04-18 04:20PM  Why Acadia Pharmaceuticals Jumped 11% Higher Today Motley Fool +10.97%
09:18AM  ACADIA Posts Narrower than Expected Loss in Q1, Sales Beat Zacks
07:51AM  Acadia: 1Q Earnings Snapshot Associated Press
07:30AM  ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results Business Wire
06:45AM  ACADIA Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
May-02-18 09:00AM  ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations Business Wire
May-01-18 11:00AM  Will ACADIA (ACAD) Disappoint Investors This Earnings Season? Zacks
09:00AM  ACADIA Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 4, 2018 Business Wire
Apr-27-18 02:35PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Acadia Pharmaceuticals Inc. - ACAD ACCESSWIRE +7.67%
08:00AM  ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile of NUPLAZID Business Wire
08:00AM  ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting Business Wire
Apr-26-18 08:10AM  Todays Research Reports on Stocks to Watch: Dare Bioscience and ACADIA ACCESSWIRE
08:07AM  Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings Benzinga
05:00AM  Heres What Just Happened With Acadia Market Exclusive
Apr-25-18 03:53PM  FDA says reviewing Acadia's Parkinson's medication, shares fall Reuters -21.93%
03:19PM  This Explains Why Acadia Pharmaceuticals Is Selling Off Today Motley Fool
02:53PM  Acadia shares plunge on report FDA is re-examining its drug CNBC
Apr-24-18 12:32PM  Lifshitz & Miller LLP Announces Investigation of Acadia Pharmaceuticals Inc., Allegiant Travel Company, Camping World Holdings, Inc., Finish Line, Inc., Myriad Genetics, Inc., Proteostasis Therapeutics, Inc., Under Armour, Inc. and United Community Bancorp PR Newswire
Apr-23-18 10:32AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acadia Pharmaceuticals Inc. - ACAD ACCESSWIRE
09:00AM  PMDAlliance and ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact of Non-Movement Symptoms of Parkinsons Disease Business Wire
Apr-20-18 02:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acadia Pharmaceuticals Inc. - ACAD ACCESSWIRE
Apr-19-18 07:04PM  Cramer's lightning round: International Paper is a 'very ... CNBC Videos
06:48PM  Cramer's lightning round: International Paper is a 'very good buy' at these prices CNBC
Apr-14-18 07:38AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acadia Pharmaceuticals Inc. - ACAD ACCESSWIRE
Apr-11-18 08:47AM  ACADIA Pharmaceuticals Inc (NASDAQ:ACAD): Does The Earnings Decline Make It An Underperformer? Simply Wall St. +7.67%
Apr-10-18 03:10PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acadia Pharmaceuticals Inc. - ACAD PR Newswire +7.52%
09:28AM  Don't Try to Catch This Falling Knife Motley Fool
08:10AM  Todays Research Reports on Stocks to Watch: ACADIA Pharmaceuticals and Menlo Therapeutics ACCESSWIRE
Apr-09-18 01:29PM  Why ACADIA Pharmaceuticals Inc. Stock Is Plunging Today InvestorPlace -23.36%
01:19PM  ACADIA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In ACADIA Pharmaceuticals Inc. To Contact The Firm PR Newswire
01:15PM  Acadia Shares Hurting On Reports Of Nuplazid Deaths Benzinga
11:42AM  Why Acadia Pharmaceuticals Is Crashing Today Motley Fool
Apr-03-18 07:05AM  Better Buy: Acadia Pharmaceuticals vs. Eli Lilly Motley Fool
Mar-27-18 08:25AM  Todays Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Immunomedics ACCESSWIRE
Mar-21-18 01:40PM  Biotech Acadia's Stock May Double On Sales Spike Investopedia
Mar-20-18 11:32AM  Is Acadia Pharmaceuticals a Buy? Motley Fool
09:00AM  ACADIA Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018 Business Wire
Mar-12-18 05:28PM  Is Acadia Pharmaceuticals Stock Now a Strong Buy? Motley Fool
Mar-07-18 07:30AM  Wired News Clearside BioMedical Reported Positive Top-line Results from Phase-3 Trial Assessing CLS-TA in Macular Edema Associated with Non-infectious Uveitis ACCESSWIRE
Mar-06-18 06:31PM  Edited Transcript of ACAD earnings conference call or presentation 27-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
09:00AM  ACADIA Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference on March 13, 2018 Business Wire
Feb-28-18 12:53PM  Why Acadia Pharmaceuticals Stock Is Crashing Today Motley Fool -20.04%
10:08AM  Heres Why ACADIA Pharmaceuticals Inc. (ACAD) Shares Are Diving Today SmarterAnalyst
Feb-27-18 07:11PM  Acadia reports 4Q loss Associated Press
04:05PM  ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results Business Wire
01:15PM  ACADIA Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
11:37AM  ACADIA Pharmaceuticals Q4 Earnings Preview Benzinga
10:55AM  Breakeven On The Horizon For ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Simply Wall St.
Feb-26-18 08:20AM  Todays Research Reports on Trending Tickers: Sage Therapeutics and ACADIA Pharmaceuticals ACCESSWIRE
Feb-25-18 03:50PM  The Week Ahead In Biotech: Earnings, PDUFA Dates And More Benzinga
Feb-20-18 05:25PM  Will ACADIA (ACAD) Disappoint Investors in Q4 Earnings? Zacks
09:00AM  George Soros Just Dumped These 2 Healthcare Stocks. Should You? Motley Fool
09:00AM  ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018 Business Wire
Feb-15-18 07:30AM  Research Report Identifies Umpqua, Westrock, Globus Medical, Procter & Gamble, ACADIA Pharmaceuticals, and Cree with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Feb-06-18 08:20AM  Todays Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Portola Pharmaceuticals ACCESSWIRE +7.02%
Jan-29-18 06:00AM  Biotech Acadia Nears Major Breakout as Sales Ramp Up Investopedia
Jan-28-18 01:10PM  5 biotech buyout candidates you should look at right now MarketWatch
Jan-26-18 10:30AM  5 Biotechs That May Surge On Takeovers Investopedia
Jan-23-18 01:13PM  What You Must Know About ACADIA Pharmaceuticals Incs (NASDAQ:ACAD) Financial Health Simply Wall St.
Jan-19-18 11:28AM  A Breakout in Aurinia Pharmaceuticals Inc May Be Imminent InvestorPlace
Jan-12-18 08:02AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Jan-10-18 08:31AM  3 Keys for Acadia Pharmaceuticals to Succeed in 2018 Motley Fool
Jan-09-18 08:10AM  Todays Research Reports on Stocks to Watch: ACADIA Pharmaceuticals Inc. and Exact Sciences Corporation ACCESSWIRE
08:03AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Jan-03-18 06:39PM  Is There An Opportunity With ACADIA Pharmaceuticals Incs (NASDAQ:ACAD) 40.91% Undervaluation? Simply Wall St.
Jan-02-18 09:00AM  ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018 Business Wire
Jan-01-18 11:25AM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : January 1, 2018 Capital Cube
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SOLAND DANIEL BDirectorMar 02Buy22.523,00067,56010,000Mar 02 06:09 PM
SOLAND DANIEL BDirectorMar 01Buy23.917,000167,3507,000Mar 02 06:09 PM
Baity GlennEVP AND GCJan 29Sale32.3936,5581,184,05583,734Jan 31 05:56 PM
Baity GlennEVP AND GCJan 10Option Exercise2.1850,179109,390120,292Jan 11 04:38 PM
Brege LauraDirectorJan 02Option Exercise8.2325,000205,80025,000Jan 04 06:23 PM
Baity GlennEVP AND GCJan 02Option Exercise2.1874,321162,020144,434Jan 04 06:24 PM
Brege LauraDirectorJan 02Sale30.0625,000751,5430Jan 04 06:23 PM
Baity GlennEVP AND GCJan 02Sale30.1474,3212,240,13970,113Jan 04 06:24 PM
BAKER BROS. ADVISORS LPDirectorNov 27Option Exercise1.3839,37854,342491,918Nov 29 04:00 PM
BAKER BROS. ADVISORS LPDirectorOct 13Option Exercise1.381,426,5901,968,69423,763,865Oct 16 05:15 PM
Baity GlennEVP AND GCOct 05Option Exercise1.9128,50054,330107,156Oct 06 06:20 PM
Baity GlennEVP AND GCOct 05Sale40.9137,5001,534,04369,656Oct 06 06:20 PM
Baity GlennEVP AND GCOct 04Option Exercise1.8511,00020,34078,656Oct 06 06:20 PM
Baity GlennEVP AND GCAug 30Option Exercise1.6216,50726,74194,163Sep 01 05:15 PM
Baity GlennEVP AND GCAug 30Sale34.8726,507924,31567,656Sep 01 05:15 PM
Baity GlennEVP AND GCAug 09Option Exercise1.6214,32223,13791,978Aug 11 05:38 PM
Baity GlennEVP AND GCAug 09Sale34.8814,322499,53477,656Aug 11 05:38 PM
Baity GlennEVP AND GCAug 04Option Exercise1.626,50010,53077,656Aug 08 06:29 PM
Baity GlennEVP AND GCJul 20Option Exercise1.6228,09745,517109,253Jul 21 05:25 PM
Baity GlennEVP AND GCJul 20Sale30.0038,0971,142,91071,156Jul 21 05:25 PM